COPENHAGEN, Denmark, July 29, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, announced that the company will host a conference call on July 30, 2015, at 9:00 a.m. Eastern Time to discuss the top-line results from a Phase 2 pediatric study of once-weekly TransCon Growth Hormone. The conference call will follow the release of the top-line results before the market opens on July 30, 2015.
Conference Call Information
Date: Thursday, July 30, 2015
Time: 9:00 a.m. Eastern Time
Dial-in (United States): (866) 682-8490
Dial-in (International): +44 (0) 1452 555131
A simultaneous webcast of the conference call will be available on the Investor Relations tab of the Ascendis Pharma website at www.ascendispharma.com. A replay of this webcast will be available on the website shortly after the conclusion of the call and will be available through August 31, 2015.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs. The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug.
The Ascendis Pharma pipeline includes TransCon Growth Hormone, a proprietary program that has completed Phase 2 studies in adults and children with growth hormone deficiency, or GHD. Ascendis Pharma is also developing its wholly-owned TransCon Treprostinil for the treatment of pulmonary arterial hypertension, or PAH. In addition to its proprietary programs, Ascendis Pharma has formed collaborations focused on leading products in large markets that are of strategic importance to its collaboration partners. These collaborations are with Sanofi in diabetes and Genentech in the field of ophthalmology.
Martin Auster, M.D.
Chief Business Officer
SOURCE Ascendis Pharma A/S